Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAGUS study of cetuximab plus modified FOLFOX6 versus modified FOLFOX6 alone as second-line therapy in KRAS wild-type metastatic colorectal cancer
2008-008282-36Phase 2Terminated
- Sponsor
- Grupo de Investigação do Cancro Digestivo
- Start
- Nov 2009
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cetuximab, oxaliplatin, fluorouracil, folinic acid and irinotecan in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by Grupo de Investigação do Cancro Digestivo. Primary endpoint: Response rate. Started Nov 2009; status: terminated.
02
Drugs
cetuximaboxaliplatinfluorouracilfolinic acidirinotecan
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2008-008282-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-008282-36.